首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Living-donor liver transplantation for hepatocellular carcinoma.
【24h】

Living-donor liver transplantation for hepatocellular carcinoma.

机译:活体肝移植治疗肝细胞癌。

获取原文
获取原文并翻译 | 示例
           

摘要

In cadaveric liver transplantation, the Milan criteria have been accepted as the selection criteria for hepatocellular carcinoma (HCC) patients in considering organ allocation. However, the situation is different in living-donor liver transplantation (LDLT), in which the donor has a strong preference for altruism. The authors describe herein their experience with LDLT for HCC patients using their patient selection criteria. From February 1999 to March 2002, right lobe LDLT was performed in 56 patients with HCC. The authors' exclusion criteria included only those with extrahepatic metastasis or vascular invasion detected during preoperative evaluation. Thirty patients (54%) were in tumor, node, metastases stage IVa and 25 patients (45%) did not meet the Milan criteria at the time of LDLT. The follow-up period was 1 to 39 months (median, 11 months). The overall survival rates at 1 and 3 years were 73% and 55%, respectively, and the latter was significantly lower than that of adult right lobe LDLT withoutHCC (71% at 3 years). Fourteen patients died because of postoperative complications without tumor recurrence. Thirty-six patients survived without recurrence and six patients had recurrence. Among the six patients with recurrence, four had survived for 11 to 36 months after LDLT. In the analysis of patients who survived longer than 3 months after transplantation, 19 of 20 within the Milan criteria survived without recurrence. However, 15 of 20 patients beyond the criteria also survived without recurrence for 3 to 33 months (median, 12 months) and three of five patients with recurrence were alive for 11 to 36 months (median, 20 months). Histopathologic grading and microscopic portal venous invasion had significant negative impact on tumor recurrence. LDLT was an effective treatment for uncontrollable hepatocellular carcinoma. Because many patients who did not meet the Milan criteria survived without tumor recurrence after transplantation, different patient selection criteria are necessary in LDLT to save thosewith advanced HCC.
机译:在尸体肝移植中,考虑器官分配时,米兰标准已被接受为肝细胞癌(HCC)患者的选择标准。但是,活体供肝移植(LDLT)的情况有所不同,在供体肝移植中供体对利他主义具有强烈的偏好。作者在此使用患者选择标准描述了他们对HCC患者进行LDLT的经历。从1999年2月至2002年3月,对56例HCC患者进行了右叶LDLT。作者的排除标准仅包括术前评估中发现有肝外转移或血管浸润的患者。 LDLT时有30例(54%)处于肿瘤,淋巴结转移IVa期,而25例(45%)未达到米兰标准。随访时间为1到39个月(中位数为11个月)。 1年和3年的总生存率分别为73%和55%,后者显着低于没有HCC的成年右叶LDLT(3年时为71%)。 14例患者死于术后并发症,无肿瘤复发。三十六例患者存活无复发,六例患者复发。在这6例复发患者中,有4例在LDLT后存活了11到36个月。在对移植后存活时间超过3个月的患者进行的分析中,符合米兰标准的20位患者中有19位存活而未复发。但是,超出标准的20名患者中有15名也存活了3至33个月(中位,为12个月),没有复发,五名复发患者中的3名还活了11至36个月(中,为20个月)。组织病理学分级和镜下门静脉浸润对肿瘤复发有明显的负面影响。 LDLT是治疗无法控制的肝细胞癌的有效方法。由于许多不符合Milan标准的患者在移植后没有肿瘤复发就可以存活,因此在LDLT中需要采用不同的患者选择标准来挽救晚期肝癌患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号